CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 110 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $73.000 thousand which missed the analyst consensus estimate of $1.100 million by 93.36 percent. This is a 96.45 percent decrease over sales of $2.055 million the same period last year.